{"nctId":"NCT00737672","briefTitle":"GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis","startDateStruct":{"date":"2008-09"},"conditions":["Renal Failure","Hemodialysis"],"count":293,"armGroups":[{"label":"VIABAHN Treatment Group","type":"EXPERIMENTAL","interventionNames":["Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface"]},{"label":"PTA Treatment Group","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Percutaneous Transluminal Angioplasty"]}],"interventions":[{"name":"GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface","otherNames":[]},{"name":"Percutaneous Transluminal Angioplasty","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hemodialysis patient with a dysfunctional or thrombosed forearm or upper arm prosthetic vascular access graft.\n* The target lesion starts less than or equal to 30 mm from the venous anastomosis.\n* The target lesion has \\> 50% stenosis as measured per protocol.\n* The patient has a maximum of one secondary stenosis.\n\nExclusion Criteria:\n\n* The age of the hemodialysis access graft is less than or equal to 30 days old from the date of the study procedure.\n* The patient has undergone an intervention (surgical or percutaneous) of the vascular access circuit less than or equal to 30 days from the date of the study procedure.\n* The secondary lesion is an occlusion.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Target Lesion Primary Patency at 6 Months","description":"Kaplan-Meier estimate of the time interval of uninterrupted patency from initial study treatment to the next access thrombosis or intervention performed on the target lesion.\n\nSix-month estimate of target lesion primary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"35.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Target Lesion Primary Patency at 12 Months","description":"Kaplan-Meier estimate of the time interval of uninterrupted patency from initial study treatment to the next access thrombosis or intervention performed on the target lesion.\n\nTwelve-month estimate of target lesion primary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Assisted Primary Patency at 6 Months","description":"Kaplan-Meier estimate of the time interval from initial study treatment to occlusion (thrombosis) of the vascular access circuit.\n\nSix-month estimate of assisted primary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null},{"groupId":"OG001","value":"51.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Assisted Primary Patency at 12 Months","description":"Kaplan-Meier estimate of the time interval from initial study treatment to occlusion (thrombosis) of the vascular access circuit.\n\nTwelve-month estimate of assisted primary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.5","spread":null},{"groupId":"OG001","value":"35.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Assisted Primary Patency at 24 Months","description":"Kaplan-Meier estimate of the time interval from initial study treatment to occlusion (thrombosis) of the vascular access circuit.\n\nTwenty-four-month estimate of assisted primary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":null},{"groupId":"OG001","value":"29.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Access Secondary Patency at 6 Months","description":"Kaplan-Meier estimate of the time interval from initial study treatment to abandonment of the vascular access circuit.\n\nSix-month estimate of secondary access patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null},{"groupId":"OG001","value":"86.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Access Secondary Patency [12 Months] Units Percentage of Subjects","description":"Kaplan-Meier estimate of the time interval from initial study treatment to abandonment of the vascular access circuit.\n\nTwelve-month estimate of secondary access secondary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null},{"groupId":"OG001","value":"78.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Access Secondary Patency [24 Months] Units Percentage of Subjects","description":"Kaplan-Meier estimate of the time interval from initial study treatment to abandonment of the vascular access circuit.\n\n24-month estimate of secondary access secondary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.9","spread":null},{"groupId":"OG001","value":"66.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Target Lesion Primary Patency at 24 Months","description":"Kaplan-Meier estimate of the time interval of uninterrupted patency from initial study treatment to the next access thrombosis or intervention performed on the target lesion.\n\nP-Value calculated from 24-month data cohort after study completion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Freedom From Major Device, Procedure and Treatment Site-related Adverse Adverse Events Through 30 Days Post-procedure","description":"The primary safety endpoint is freedom from major device, procedure and treatment site-related adverse events through 30 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Circuit Primary Patency","description":"Kaplan-Meier estimate of the time interval from initial study treatment to the next access thrombosis or intervention performed within the vascular access circuit.\n\nP-Value calculated from 24-month data cohort. Six-month estimate of circuit primary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"29.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Circuit Primary Patency [12 Months] Units Percentage of Subjects","description":"Kaplan-Meier estimate of the time interval from initial study treatment to abandonment of the vascular access circuit.\n\nTwelve-month estimate of secondary access secondary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Circuit Primary Patency [24 Months] Units Percentage of Subjects","description":"Kaplan-Meier estimate of the time interval from initial study treatment to abandonment of the vascular access circuit.\n\nTwelve-month estimate of secondary access secondary patency derived from Kaplan-Meier curve.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success","description":"The resumption of normal dialysis for at least one session following study treatment (Index Procedure).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Anatomic Success","description":"Less than 30 percent residual stenosis following study treatment (Index Procedure).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Procedural Success","description":"Participants were considered to have Procedural Success if they achieved both anatomic success and clinical success.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":78,"n":145},"commonTop":["Chest pain"]}}}